MKI67 and neoplasm: A significant reduction in tumor cell proliferation (as assessed by Ki-67 expression) was found in the tumors treated with the combination of melittin and docetaxel (5.7 ± 0.8%) relative to vehicle (59.8 ± 1.7%), compared to either melittin (31.7 ± 1.3%) or docetaxel alone (21.0 ± 1.3%, one-way ANOVA, p < 0.01, mean ± SEM).